Regression to the mean in multiple sclerosis
- 1 November 2006
- journal article
- other
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 12 (6) , 826-829
Abstract
In order to ensure sufficient disease activity, patients with relapsing remitting (RR) multiple sclerosis (MS) are often included in randomized placebo-controlled trials, only if they have a high baseline activity. These patients, whose evolution is unusual in the pre-study period, will tend to show a more usual behavior when followed up over a period of time. This phenomenon is known as regression to the mean. Regression to the mean should be taken into account in correctly interpreting long-term studies of cohorts treated without a placebo control group, which use the baseline period as control. The aim of this study was to evaluate the relevance of this phenomenon in a non-treated cohort of RRMS patients, selected with similar criteria to those used in randomized placebo-controlled clinical trials. Forty-four patients with definite RRMS, with two or more relapses in the previous two years, and a baseline EDSS ≤ 5.5 were prospectively followed. The mean number of relapses spontaneously decreased from 1.72 (SD: 1.4) in the year prior to enrolment, to 1.0 (SD: 1.3) during the first year of follow-up (PB < 0.05). Regression to the mean may explain as much as 40% of the reduction in the relapse rate from the baseline period to the period on-study.Keywords
This publication has 15 references indexed in Scilit:
- Lack of evidence for use of glatiramer acetate in multiple sclerosisThe Lancet Neurology, 2004
- Disease-modifying therapy in MS: a critical review of the literatureJournal of Neurology, 2004
- Interferons in relapsing remitting multiple sclerosis: a systematic reviewThe Lancet, 2003
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosisNeurology, 1998
- Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosisThe Lancet, 1997
- Meta-analysis of the placebo-treated groups in clinical trials of progressive MSNeurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995